Medtronic Diabetes In The News

mySentry

2012-01-04T13:31:36.000Z

MINNEAPOLIS – January 4, 2012 – Today, Medtronic, Inc. (NYSE:MDT) announced U.S. Food and Drug Administration (FDA) approval and U.S. market launch of the first-of-its-kind mySentry™ Remote Glucose Monitor, which allows a parent or caregiver to monitor from another room a patient’s MiniMed Paradigm® REAL-Time Revel™ System. The remote glucose monitor also marks the launch of a new category of Connected Care solutions that will provide people with diabetes and their caregivers convenient options to access their diabetes management information.

iPro2

2011-11-23T23:41:58.000Z

MINNEAPOLIS – November 22, 2011 – Medtronic, Inc. (NYSE:MDT) today announced the Food and Drug Administration (FDA) approval of iPro®2, a next generation Professional continuous glucose monitoring (CGM) system and the latest in a series of recent diabetes technology approvals and innovations from the company. iPro2 simplifies Professional CGM and enables healthcare providers to obtain a more complete picture of glucose control for the patients they treat. Professional CGM is used by healthcare providers to reveal low (hypoglycemia) and high (hyperglycemia) glucose excursions that can lead to the dangerous health complications of diabetes. These excursions often go unnoticed with traditional A1C tests and standard glucose meter measurements.

Enlite IDE

2011-11-21T20:27:08.000Z

MINNEAPOLIS – Nov. 9, 2011 – Medtronic, Inc. (NYSE: MDT) today announced a new United States investigational device exemption study to evaluate the accuracy of six-day use in adults with diabetes of its Enlite™ Sensor, the company’s latest innovation in continuous glucose monitoring (CGM) technology for people with diabetes. The study will evaluate Enlite, a glucose sensor for CGM designed to offer improved hypoglycemic detection and comfort compared to current CGM sensors. CGM provides a more complete picture of glucose control because it can reveal high and low glucose levels that periodic fingerstick testing might miss.

ASPIRE

2011-11-21T20:30:53.000Z

MINNEAPOLIS – October 28, 2011 – In our continued commitment to develop an artificial pancreas, Medtronic, Inc. (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) to conduct a pivotal in-home clinical trial protocol for the ASPIRE study of the MiniMed Paradigm® System featuring Low Glucose Suspend (LGS) automation. FDA approval of the IDE makes Medtronic’s ASPIRE study the first in-home pivotal trial of a closed loop system for Type 1 diabetes management.

Insulin Pump Security Update

2011-10-27T16:59:05.000Z

Medtronic takes patient safety and device security very seriously and we appreciate the security community bringing new information on the possibility of a cyber-attack on our insulin pumps. We have been increasing our focus on the prevention of tampering with our products and look forward to partnering with the security, healthcare and diabetes communities to develop ways to better protect patients from the risk of tampering, which is necessary to keep pace with a new and rapidly evolving technology landscape.

We have taken a number of steps to address this matter including conducting an in-depth risk/benefit analysis to clearly assess the potential risk, evaluating the best encryption and security technologies for incorporation into our products and design process, and finally, committing to establish an industry working group that engages relevant stakeholders from the diabetes, healthcare and security community to develop new approaches and best practices to device security.

Because insulin pumps are widely used by patients with diabetes for tight blood sugar control and lifestyle flexibility, we are also working to assure both patients and doctors that at this time we believe that the risk is low and the benefits of the therapy outweigh the risk of an individual criminal attack.

ADA Press Release

2011-09-09T22:17:50.000Z

SAN DIEGO – June 25, 2011 – Research presented at the American Diabetes Association's 71st Scientific Sessions (ADA) this week adds to the clinical evidence for Medtronic’s sensor-augmented insulin pump therapy for improved glucose control for people with type 1 diabetes. Medtronic has the only FDA-approved sensor-augmented insulin pump (an insulin pump that integrates continuous glucose monitoring into one device).

Bayer Press Release

2011-09-09T22:14:06.000Z

MINNEAPOLIS AND TARRYTOWN, NY ― May 9, 2011― Medtronic, Inc. (NYSE: MDT) and Bayer HealthCare have expanded their international alliance to now include the United States and will work exclusively to develop innovative next generation diabetes management solutions for patients worldwide.

CareLink for Mac Press Release

2011-09-09T22:18:09.000Z

MINNEAPOLIS – April 4, 2011 – Medtronic, Inc. today announced the Food and Drug Administration (FDA) approval and the market launch of CareLink® Personal 5.4 Therapy Management Software for the Mac OS platform. CareLink Personal is a web-based program that helps people with diabetes assess their glucose control through easy-to-read reports, charts, and graphs. The software analyzes data from the user’s insulin pump, continuous glucose monitoring (CGM) device, and blood glucose meter to uncover trends and patterns in daily management that meters and logbooks alone cannot reveal.

Carelink Pro 3.0 Launch

2011-10-06T22:53:06.000Z

Medtronic, Inc. today announced the Food and Drug Administration (FDA) approval and the market launch of CareLink® Pro 3.0 Therapy Management Software, the first software program to offer advanced decision support to healthcare professionals managing diabetes.

STAR 3 Results

2011-10-06T23:03:20.000Z

In the longest and largest randomized, controlled study of sensor-augmented insulin pump therapy in type 1 diabetes, adult and pediatric patients using the Medtronic MiniMed Paradigm® REAL-Time System achieved better glucose control without an increase in hypoglycemia compared to multiple daily insulin injections (MDI), the most common approach to care today.

ASPIRE Pivotal Study of Low Glucose Suspend

2011-10-06T22:50:20.000Z

Demonstrating its dedication to close the loop for diabetes management, Medtronic, Inc. (NYSE:MDT) today announced that the first patient has been enrolled as part of the ASPIRE study of the MiniMed Paradigm x54 System featuring Low Glucose Suspend automation.

Medtronic receives FDA approval

2011-10-06T22:58:02.000Z

Medtronic, Inc. (NYSE:MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval for the MiniMed Paradigm® REAL-Time Revel™ System, the next generation of the industry’s only integrated diabetes management system (insulin pump therapy, continuous glucose monitoring (CGM) and diabetes therapy management software).